These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 21173125)

  • 21. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
    Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
    Ahmad F; Mandava S; Das BR
    Cancer Invest; 2010 Jan; 28(1):63-73. PubMed ID: 19995225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation.
    Mori Y; Yoshimoto G; Kumano T; Miyamoto T; Iino T; Takenaka K; Iwasaki H; Harada N; Kinukawa N; Nagafuji K; Teshima T; Shimoda K; Akashi K; Harada M
    Eur J Haematol; 2007 Jul; 79(1):17-24. PubMed ID: 17598835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Correlation of NPM1, FLT3-ITD mutations with leukocyte count and myeloblasts percentage in AML patients with normal karyotype].
    Su L; Li W; Cui JW; Tan YH; Yang Y; Liu XL; Yu P; Hu RP; Wang LL; Gao SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):571-5. PubMed ID: 23815900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia.
    Del Poeta G; Ammatuna E; Lavorgna S; Capelli G; Zaza S; Luciano F; Ottone T; Del Principe MI; Buccisano F; Maurillo L; Panetta P; de Fabritiis P; Stasi R; Venditti A; Amadori S; Lo Coco F
    Br J Haematol; 2010 May; 149(3):383-7. PubMed ID: 20148885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A study of NPM1 and FLT3 gene mutations in acute myeloid leukemia].
    Wu DP; Yan LZ; Yang L; Chen SN; Wu XJ; Liang JY
    Zhonghua Nei Ke Za Zhi; 2007 Nov; 46(11):907-10. PubMed ID: 18261272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
    Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
    Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular and clinicopathologic characterization of AML with isolated trisomy 4.
    Bains A; Lu G; Yao H; Luthra R; Medeiros LJ; Sargent RL
    Am J Clin Pathol; 2012 Mar; 137(3):387-94. PubMed ID: 22338050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
    Dufour A; Schneider F; Hoster E; Benthaus T; Ksienzyk B; Schneider S; Kakadia PM; Sauerland MC; Berdel WE; Büchner T; Wörmann B; Braess J; Subklewe M; Hiddemann W; Bohlander SK; Spiekermann K;
    Ann Hematol; 2012 Jul; 91(7):1051-63. PubMed ID: 22362118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J; Wang T; Li S; Lin L; Gang Y
    Ai Zheng; 2007 Jan; 26(1):58-63. PubMed ID: 17222369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
    Ravandi F; Jilani I; Estey E; Kantarjian H; Dey A; Aguilar C; Jitkaroon C; Giles F; O'Brien S; Keating M; Albitar M
    Leuk Res; 2007 Jun; 31(6):791-7. PubMed ID: 17156841
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype.
    Zhang Y; Zhang M; Yang L; Xiao Z
    Leuk Res; 2007 Jan; 31(1):109-11. PubMed ID: 16678898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.
    Rausei-Mills V; Chang KL; Gaal KK; Weiss LM; Huang Q
    Am J Clin Pathol; 2008 Apr; 129(4):624-9. PubMed ID: 18343790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.